Enanta Pharmaceuticals, Inc. (ENTA:NASDAQ) closed at $10.43 on November 2, 2026, down 2.61% on the day. The stock trades 39.2% below its 52-week high of $17.15 and 2.8% above its 52-week low of $10.15. Over the past year, it lost 3.6%. Enanta Pharmaceuticals, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 31, 2025, ENTA closed higher on 128 days (51%). Its best day was February 24, 2026 (+9.34%) and its worst was March 5, 2026 (-10.84%). The stock moved 10% or more in a single session 1 time. It opened at least 5% above the previous day's high 1 time.
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on four disease targets: Hepatitis C virus (HCV), Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). Its lead product is paritaprevir, a protease inhibitor designed for use against HCV. The company also develops HCV protease inhibitor in phase III development with AbbVie, as well as a HCV program using a different class of molecules known as cyclophilin inhibitors. In addition, it has a program in non-alcoholic steatohepatitis; and discovers programs in other areas of viral infection and liver disease. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with AbbVie to develop and commercialize HCV NS3 and NS3/4A protease inhibitors. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Find more stocks like ENTA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.